Select therapeutic use:
Indications for OPTIRAY 240:
Cerebral angiography and venography. For contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.
Individualize. Visualization of carotid or vertebral arteries: 2–12mL, repeat as necessary. Aortic arch inj for simultaneous four vessel study: 20–50mL; total procedure doses should not exceed 200mL. Venography: 50–100mL per extremity; max 250mL. Head imaging: 100–250mL; max 250mL. Body imaging: Bolus inj: 35–100mL; Infusion: 70-200mL; max 250mL. IV urography: 75–100mL; may use higher dose of 2mL/kg (max 200mL) for optimum results.
See full labeling. Not for intrathecal use; may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Risk of serious thromboembolic events (eg, MI, stroke), neurologic sequelae, including paralysis. Suspected thrombosis, phlebitis, severe ischemic disease, local infection: caution in venography. Advanced arteriosclerosis, severe hypertension, cardiac decompensation, senility, recent cerebral thrombosis/embolism, and migraine: use extreme caution in cerebral arteriography. Avoid angiography with homocystinuria. Renal or hepatic impairment. Anuria. CHF. Pulmonary hypertension. Chronic pulmonary emphysema. Dehydration. Multiple myeloma or other paraproteinemia. Homozygous sickle cell disease. Pheochromocytoma. Thyroid disorder. Diabetes. Myasthenia gravis. Anesthetized patients. Monitor blood pressure and ECG. Maintain adequate hydration. Avoid extravasation. Elderly. Pregnancy. Nursing mothers.
Patients with hepatic or biliary disorder that have received cholecystographic agents recently; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Radiopaque contrast agent.
Nausea, headache, hypersensitivity; cardiovascular, CNS, respiratory, skin reactions, endocrine, others (see full labeling).
OPTIRAY 240: Bottles (50mL)—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 125mL)—20, RFID-Tagged syringes (125ml)—20; OPTIRAY 300: Bottles (50mL—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 100mL, 125mL)—20, RFID-Tagged syringes (100mL, 125mL)—20; OPTIRAY 320: Vials (20mL, 30mL)—25, Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (30mL, 50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20; OPTIRAY 350: Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20